Evidence map›Paper›PMID 41090793›Full record

ArticleCells2025

The GR-LEDGF/p75-HSP27 Axis Contributes to Cross-Resistance Between Enzalutamide and Docetaxel in Prostate Cancer.

Pedro T Ochoa, Evelyn S Sanchez-Hernandez, Alfonso M Duran, Kai Wen Cheng, Joel Philip, Tise Suzuki, Julia J Unternaehrer, Julie Dutil, Bhaskar Das, Rituparna Ganguly and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Pedro T OchoaCenter for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
Evelyn S Sanchez-HernandezCenter for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
Alfonso M DuranCenter for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
Kai Wen ChengCenter for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
Joel PhilipCenter for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
Tise SuzukiCenter for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
Julia J UnternaehrerCenter for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.ORCID 0000-0001-5864-4704
Julie DutilUniversity of Puerto Rico Comprehensive Cancer Center, San Juan, PR 00921, USA.
Bhaskar DasDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14215, USA.
Rituparna GangulyCaris Life Sciences, Phoenix, AZ 85040, USA.
Yasmine BacaCaris Life Sciences, Phoenix, AZ 85040, USA.
David de SemirCaris Life Sciences, Phoenix, AZ 85040, USA.ORCID 0000-0001-8250-2183
Charles WangDepartment of Basic Sciences, Center for Genomics, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
Isaac KremskyDepartment of Basic Sciences, Division of Biomedical Engineering Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
Carlos A CasianoCenter for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.ORCID 0000-0002-7320-4333

Funding

NIH-LLU Initiative for Maximizing Student DiversityR25GM060507 · NIGMS · LOMA LINDA UNIVERSITY · PI DE LEON, MARINO · 2001 to 2022
$11.3M
Role and Theranostics Potential of Enolase in Prostate Cancer Health DisparitiesR21CA280647 · NCI · LOMA LINDA UNIVERSITY · PI ALMAGUEL, FRANKIE G, CASIANO, CARLOS A. · 2023 to 2024
$537k
Glucocorticoid signaling, taxane resistance, and prostate cancer mortality disparityR21CA226654 · NCI · LOMA LINDA UNIVERSITY · PI CASIANO, CARLOS A. · 2019 to 2020
$513k
NCI NIH HHS R21 CA226654NCI NIH HHS R21 CA280647NIGMS NIH HHS R25 GM060507NIH HHS 1R21CA226654-01A1NIH HHS 1R21CA280647-01A1NIH HHS 5R25GM060507-22
6 · The paper itself

Abstract

An emerging challenge in prostate cancer (PCa) treatment is the development of drug cross-resistance, wherein resistance to enzalutamide (ENZ), an androgen receptor signaling inhibitor (ARSI), also confers resistance to subsequent ARSI and docetaxel (DTX) treatments. The mechanisms underlying this drug cross-resistance remain unclear. Through RNA sequencing, we identified 93 overlapping differentially expressed genes (DEGs) in ENZ- and DTX-resistant PCa cells. Among the DEGs,

Indexed as

Adaptor Proteins, Signal TransducingBenzamidesDocetaxelDrug Resistance, NeoplasmHSP27 Heat-Shock ProteinsPhenylthiohydantoinProstatic NeoplasmsReceptors, GlucocorticoidAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHeat-Shock ProteinsHumansMaleMiceMolecular ChaperonesAdaptor Proteins, Signal TransducingBenzamidesDocetaxelenzalutamideHeat-Shock ProteinsHSP27 Heat-Shock ProteinsHSPB1 protein, humanMolecular ChaperonesNitrilesPhenylthiohydantoinReceptors, Glucocorticoiddocetaxeldrug cross-resistanceenzalutamideglucocorticoid receptorHSP27LEDGF/p75prostate cancerRNA sequencing

Identifiers

PMID41090793
PMCPMC12523889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.